Table 2.
Predictors of resistant disease
| Variable | OR (95% CI) | P |
|---|---|---|
| Age, per yr | 0.98 (0.95–1.01) | 0.15 |
| Male | 0.55 (0.18–1.68) | 0.29 |
| MPO | 0.70 (0.24–2.09) | 0.53 |
| Sinus | 4.75 (1.60–14.13) | 0.005 |
| Pulmonary | 1.12 (0.39–3.19) | 0.84 |
| RPGN | 0.95 (0.33–2.75) | 0.93 |
| Initial BVAS-WG, per point | 1.04 (0.87–1.23) | 0.67 |
| Relapsing disease | 1.57 (0.31–8.03) | 0.59 |
| PLEX | 1.08 (0.35–3.36) | 0.90 |
| ANCA declinea | 0.24 (0.07–0.81) | 0.02 |
ANCA, antineutrophil cytoplasmic antibody; BVAS-WG, Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis; CI, confidence interval; MPO, myeloperoxidase; OR, odds ratio; PLEX, plasma exchange; RPGN, rapidly progressive glomerulonephritis.
Resistant disease was defined as achieving complete remission greater than 150 days after initiating induction of remission therapy.
a
ANCA decline refers to a 10-fold reduction in the ANCA titer at 4 months.